PL3202789T3 - Przeciwciała anty-vla-4 - Google Patents

Przeciwciała anty-vla-4

Info

Publication number: PL3202789T3
Authority: PL; Poland
Prior art keywords: vla; antibodies
Prior art date: 2010-04-16

Application number

PL17163411T

Other languages

English (en)

Inventor

Alexey A. Lugovskoy

Frederick R. Taylor

Karen Mclachlan

Original Assignee

Biogen Ma Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-16

Filing date

2011-04-15

Publication date

2020-09-21

2011-04-15 Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.

2020-09-21 Publication of PL3202789T3 publication Critical patent/PL3202789T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Oncology (AREA)
Mycology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Neurology (AREA)
Plant Pathology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)

PL17163411T 2010-04-16 2011-04-15 Przeciwciała anty-vla-4 PL3202789T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32494410P	2010-04-16	2010-04-16
EP11730120.0A EP2558499B1 (en)	2010-04-16	2011-04-15	Anti-vla-4 antibodies
PCT/US2011/032641 WO2011130603A2 (en)	2010-04-16	2011-04-15	Anti-vla-4 antibodies
EP17163411.6A EP3202789B1 (en)	2010-04-16	2011-04-15	Anti-vla-4 antibodies

Publications (1)

Publication Number	Publication Date
PL3202789T3 true PL3202789T3 (pl)	2020-09-21

Family

ID=44628095

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL18205524T PL3466977T3 (pl)	2010-04-16	2011-04-15	Przeciwciała anty-vla-4
PL11730120T PL2558499T3 (pl)	2010-04-16	2011-04-15	Przeciwciała anty-VLA-4
PL17163411T PL3202789T3 (pl)	2010-04-16	2011-04-15	Przeciwciała anty-vla-4

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL18205524T PL3466977T3 (pl)	2010-04-16	2011-04-15	Przeciwciała anty-vla-4
PL11730120T PL2558499T3 (pl)	2010-04-16	2011-04-15	Przeciwciała anty-VLA-4

Country Status (25)

Country	Link
US (5)	US20140161794A1 (pl)
EP (4)	EP3466977B1 (pl)
JP (5)	JP6085554B2 (pl)
KR (1)	KR20130066584A (pl)
CN (1)	CN103038257A (pl)
AU (1)	AU2011239512B2 (pl)
BR (1)	BR112012026403B1 (pl)
CA (1)	CA2794863C (pl)
CY (2)	CY1119154T1 (pl)
DK (3)	DK3202789T3 (pl)
EA (1)	EA201291065A1 (pl)
ES (4)	ES2805873T3 (pl)
HR (2)	HRP20171045T1 (pl)
HU (2)	HUE050858T2 (pl)
LT (2)	LT3202789T (pl)
ME (2)	ME02793B (pl)
MX (1)	MX340683B (pl)
NZ (1)	NZ602676A (pl)
PL (3)	PL3466977T3 (pl)
PT (2)	PT3202789T (pl)
RS (2)	RS60897B1 (pl)
SG (3)	SG10202112020VA (pl)
SI (2)	SI3202789T1 (pl)
SM (2)	SMT201700334T1 (pl)
WO (1)	WO2011130603A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2805873T3 (es)	2010-04-16	2021-02-15	Biogen Ma Inc	Anticuerpos anti-VLA-4
KR20160030200A (ko) *	2013-07-05	2016-03-16	바이오젠 엠에이 인코포레이티드	뇌졸중 치료용 조성물 및 방법
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
EP3355920A4 (en)	2015-09-29	2019-05-15	Celgene Corporation	PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
WO2017220989A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Anti-pd-l1 and il-2 cytokines
AU2017329024A1 (en)	2016-09-19	2019-03-21	Celgene Corporation	Methods of treating immune disorders using pd-1 binding proteins
US10766958B2 (en)	2016-09-19	2020-09-08	Celgene Corporation	Methods of treating vitiligo using PD-1 binding antibodies
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP2019136398A (ja) *	2018-02-14	2019-08-22	株式会社三洋物産	遊技機
JP2019136399A (ja) *	2018-02-14	2019-08-22	株式会社三洋物産	遊技機
CN112867394B9 (zh)	2018-06-04	2024-12-06	马萨诸塞州渤健公司	具有降低的效应功能的抗vla-4抗体
EP4153317A1 (en)	2020-05-19	2023-03-29	Janssen Biotech, Inc.	Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
BR102020016890A2 (pt)	2020-08-19	2022-05-03	Fundação Oswaldo Cruz	Proteina, polinucleotídeo, vetor, célula hospedeira, composição, método para tratar uma doença, método in vitro para prognosticar esclerose múltipla, e, uso de uma proteína ou composição
WO2022133169A1 (en)	2020-12-18	2022-06-23	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
CN117396226A (zh)	2021-05-18	2024-01-12	詹森生物科技公司	包含t细胞重定向治疗剂和抗cd44治疗剂的组合物

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
JPS6081397A (ja)	1983-10-06	1985-05-09	荒川化学工業株式会社	中性抄紙方法
US4494880A (en)	1984-03-14	1985-01-22	Su Wen Kuang	Foldable clock dial
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
DE3668186D1 (de)	1985-04-01	1990-02-15	Celltech Ltd	Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
NZ215865A (en)	1985-04-22	1988-10-28	Commw Serum Lab Commission	Method of determining the active site of a receptor-binding analogue
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
HU196394B (en)	1986-06-27	1988-11-28	Richter Gedeon Vegyeszet	Process for preparing 2-halogenated ergoline derivatives
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
SE461013B (sv)	1988-02-11	1989-12-18	Christian Wesslau	Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5272263A (en)	1989-04-28	1993-12-21	Biogen, Inc.	DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en)	1989-04-28	1993-06-08	Biogen, Inc.	Monoclonal antibodies against CDX
US6307025B1 (en)	1989-04-28	2001-10-23	Biogen, Inc.	VCAM fusion proteins and DNA coding therefor
US6033665A (en)	1989-09-27	2000-03-07	Elan Pharmaceuticals, Inc.	Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en)	1989-09-27	1993-11-09	Rubin Lee L	Blood-brain barrier model
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5192746A (en)	1990-07-09	1993-03-09	Tanabe Seiyaku Co., Ltd.	Cyclic cell adhesion modulation compounds
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
GB9019812D0 (en)	1990-09-11	1990-10-24	Scotgen Ltd	Novel antibodies for treatment and prevention of infection in animals and man
CA2103059C (en)	1991-06-14	2005-03-22	Paul J. Carter	Method for making humanized antibodies
JPH07506091A (ja)	1992-01-13	1995-07-06	バイオゲン　インコーポレイテッド	喘息の処置
US5871734A (en)	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US5932214A (en)	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
EP0625912B1 (en)	1992-02-12	1997-04-16	Biogen, Inc.	Treatment for inflammatory bowel disease
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
CA2148712C (en)	1992-11-13	2012-01-17	Thalia Papayannopoulou	Peripheralization of hematopoietic stem cells
NZ261259A (en)	1993-01-12	1996-12-20	Biogen Inc	Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
CA2155540A1 (en)	1993-02-08	1994-08-18	Frank Collins	Methods for treating amyotrophic lateral sclerosis with cntf
JP3593343B2 (ja)	1993-02-09	2004-11-24	バイオジェンインコーポレイテッド	インシュリン依存型糖尿病の治療
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US6432404B1 (en)	1993-12-23	2002-08-13	Icos Corporation	Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
WO1995019790A1 (en)	1994-01-25	1995-07-27	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) *	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
US5672622A (en)	1994-04-21	1997-09-30	Berlex Laboratories, Inc.	Treatment of multiple sclerosis
SE504751C2 (sv)	1994-06-30	1997-04-21	Lars Fredriksson	Kopplingslänk
US5498156A (en)	1994-09-02	1996-03-12	Ipsco Enterprises Inc.	Dual-purpose guide and drum cleaner for Steckel mill coiler furnace
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE19541844C1 (de)	1995-11-09	1997-07-24	Gsf Forschungszentrum Umwelt	Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
BRPI9707379C8 (pt)	1996-02-09	2017-12-12	Abbott Biotech Ltd	composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
ES2271971T3 (es)	1996-07-25	2007-04-16	Biogen Idec Ma Inc.	Inhibidores de la adhesion celular.
US7361331B2 (en)	1996-10-18	2008-04-22	Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food	Plant bioreactors
ES2301183T3 (es)	1996-12-03	2008-06-16	Amgen Fremont Inc.	Anticuerpo completamente humano que se une al receptor del egfr.
US6890526B2 (en)	1997-05-06	2005-05-10	Vanderbilt University	Methods and reagents for the treatment of multiple sclerosis
CN1265675A (zh)	1997-07-31	2000-09-06	伊兰药品公司	抑制由vla－4介导的白细胞粘着的苄基化合物
US6153653A (en)	1997-11-26	2000-11-28	Protarga, Inc.	Choline compositions and uses thereof
WO1999033455A1 (en)	1997-12-30	1999-07-08	Bioabsorbable Concepts, Inc.	Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system
ATE256659T1 (de)	1998-05-28	2004-01-15	Biogen Inc	Ein vla-4-inhibitor: omepupa-v
US7232830B2 (en)	1998-06-26	2007-06-19	Elaine A Delack	Method for treatment of neurodegenerative diseases and effects of aging
SK287601B6 (sk) *	1998-09-14	2011-03-04	Board Of Regents, The University Of Texas System	Použitie protilátky alebo jej fragmentu viažuceho antigén na výrobu farmaceutickej kompozície na liečenie mnohonásobného myelómu a na inhibíciu resorpcie kostí
US6355623B2 (en)	1998-09-24	2002-03-12	Hopital-Sainte-Justine	Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
DE19853487A1 (de)	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
EP1119368A2 (en)	1999-03-03	2001-08-01	Biogen, Inc.	Methods of modulating lipid metabolism and storage
WO2001045725A2 (en)	1999-12-23	2001-06-28	Ancile Pharmaceuticals, Inc.	Treatment for inflammatory bowel disease (ibd) and related conditions
MXPA02007291A (es)	2000-01-27	2002-11-29	American Cyanamid Co	Metodo para preparar derivados de acido alfa-sulfonil hidroxamico.
EP2258834B1 (en)	2000-03-31	2015-09-23	The Scripps Research Institute	Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US8288322B2 (en)	2000-04-17	2012-10-16	Dyax Corp.	Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US6537243B1 (en)	2000-10-12	2003-03-25	Abbott Laboratories	Device and method for obtaining interstitial fluid from a patient for diagnostic tests
WO2002100428A1 (en)	2001-06-11	2002-12-19	Transition Therapeutics Inc.	Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
DK2224012T3 (da)	2001-12-17	2013-05-13	Corixa Corp	Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US20040203031A1 (en)	2002-04-03	2004-10-14	University Of Pennsylvania	Methods for determining drug responsiveness
KR20040084911A (ko)	2002-02-15	2004-10-06	코넬 리서치 파운데이션 인코포레이티드	희소돌기아교세포 선조 세포를 이용한 선천적으로미엘린화되지 않은 전뇌의 미엘린화
SI1485127T1 (sl)	2002-02-25	2011-09-30	Elan Pharm Inc	Dajanje aktivne snovi za zdravljenje vnetja
WO2003074679A2 (en) *	2002-03-01	2003-09-12	Xencor	Antibody optimization
EP3321282A1 (en)	2002-09-27	2018-05-16	Xencor, Inc.	Optimized fc variants and methods for their generation
AU2003284246A1 (en)	2002-10-16	2004-05-04	Samuel F. Hunter	Method for treatment of demyelinating central nervous system disease using gm-csf
ATE455853T1 (de)	2002-11-22	2010-02-15	Chugai Pharmaceutical Co Ltd	Antikörper gegen geschädigtes gewebe
AU2004207536B2 (en)	2003-01-24	2010-05-20	Elan Pharmaceuticals Inc.	Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EP1592440A4 (en)	2003-02-10	2007-07-11	Elan Pharm Inc	IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME
US20050074443A1 (en)	2003-10-03	2005-04-07	Treadwell Benjamin V.	Methods of attenuating autoimmune disease and compositions useful therefor
WO2005063815A2 (en)	2003-11-12	2005-07-14	Biogen Idec Ma Inc.	Fcϝ receptor-binding polypeptide variants and methods related thereto
AU2004290070A1 (en)	2003-11-12	2005-05-26	Biogen Idec Ma Inc.	Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
MY162179A (en)	2004-04-01	2017-05-31	Elan Pharm Inc	Steroid sparing agents and methods of using same
AU2005244751A1 (en)	2004-04-16	2005-12-01	Genentech, Inc.	Method for augmenting B cell depletion
CA2478458A1 (en)	2004-08-20	2006-02-20	Michael Panzara	Treatment of pediatric multiple sclerosis
HRP20120171T1 (hr)	2004-09-03	2012-03-31	Genentech	Humanizirani anti-beta 7 antagonisti i njihove uporabe
EP1827491A4 (en)	2004-11-19	2010-07-14	Biogen Idec Inc	TREATMENT OF MULTIPLE SCLEROSIS
EP1833509A4 (en)	2004-12-03	2008-12-03	Biogen Idec Inc	DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
US7678371B2 (en)	2005-03-04	2010-03-16	Biogen Idec Ma Inc.	Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
CA2610800A1 (en)	2005-06-09	2006-12-14	Ucb Pharma, S.A.	2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
WO2007008943A2 (en)	2005-07-08	2007-01-18	Xencor, Inc.	Optimized anti-ep-cam antibodies
EP2839843B1 (en)	2006-05-25	2018-06-20	Biogen MA Inc.	VLA-1 antagonist for use in treating stroke
WO2008021954A2 (en)	2006-08-09	2008-02-21	Biogen Idec Ma Inc.	Method for distribution of a drug
US8771689B2 (en)	2006-12-11	2014-07-08	The Board Of Trustees Of The Leland Stanford Junior University	Alpha B-crystallin as a therapy for ischemia or inflammation
US8931218B2 (en)	2007-04-19	2015-01-13	Oldcastle Building Products, Inc.	Modular brick or block outdoor structures
KR20100021601A (ko)	2007-05-14	2010-02-25	바이오겐 아이덱 엠에이 인코포레이티드	단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
LT2170390T (lt)	2007-06-14	2019-01-10	Biogen Ma Inc.	Natalizumabo antikūnų kompozicijos
US20090004189A1 (en)	2007-06-18	2009-01-01	Genentech, Inc.	Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
DE102007049542A1 (de)	2007-10-16	2009-04-23	Neue Magnetodyn Gmbh	Implantierbare Vorrichtung, System zum Erzeugen lokalisierter elektromagnetischer Felder im Bereich eines Implantats und Spulenanordnung
EP2050462A1 (en)	2007-10-18	2009-04-22	PAION Deutschland GmbH	Improved treatment of stroke patients
ES2805873T3 (es) *	2010-04-16	2021-02-15	Biogen Ma Inc	Anticuerpos anti-VLA-4
WO2013057092A1 (en)	2011-10-17	2013-04-25	Westfaelische Wilhelms-Universitaet Muenster	Methods of risk assessment of pml and related apparatus
CN112867394B9 (zh) *	2018-06-04	2024-12-06	马萨诸塞州渤健公司	具有降低的效应功能的抗vla-4抗体

2011
- 2011-04-15 ES ES17163411T patent/ES2805873T3/es active Active
- 2011-04-15 SI SI201131902T patent/SI3202789T1/sl unknown
- 2011-04-15 SG SG10202112020VA patent/SG10202112020VA/en unknown
- 2011-04-15 SI SI201131238T patent/SI2558499T1/sl unknown
- 2011-04-15 DK DK17163411.6T patent/DK3202789T3/da active
- 2011-04-15 CN CN2011800296749A patent/CN103038257A/zh active Pending
- 2011-04-15 ME MEP-2017-148A patent/ME02793B/me unknown
- 2011-04-15 EP EP18205524.4A patent/EP3466977B1/en active Active
- 2011-04-15 RS RS20200950A patent/RS60897B1/sr unknown
- 2011-04-15 PL PL18205524T patent/PL3466977T3/pl unknown
- 2011-04-15 EA EA201291065A patent/EA201291065A1/ru unknown
- 2011-04-15 AU AU2011239512A patent/AU2011239512B2/en active Active
- 2011-04-15 US US13/641,199 patent/US20140161794A1/en not_active Abandoned
- 2011-04-15 ES ES11730120.0T patent/ES2633105T3/es active Active
- 2011-04-15 EP EP17163411.6A patent/EP3202789B1/en active Active
- 2011-04-15 PT PT171634116T patent/PT3202789T/pt unknown
- 2011-04-15 LT LTEP17163411.6T patent/LT3202789T/lt unknown
- 2011-04-15 EP EP21218415.4A patent/EP4032912B1/en active Active
- 2011-04-15 HU HUE17163411A patent/HUE050858T2/hu unknown
- 2011-04-15 RS RS20170701A patent/RS56082B1/sr unknown
- 2011-04-15 WO PCT/US2011/032641 patent/WO2011130603A2/en not_active Ceased
- 2011-04-15 ES ES21218415T patent/ES3039529T3/es active Active
- 2011-04-15 PL PL11730120T patent/PL2558499T3/pl unknown
- 2011-04-15 DK DK18205524.4T patent/DK3466977T3/da active
- 2011-04-15 BR BR112012026403-6A patent/BR112012026403B1/pt active IP Right Grant
- 2011-04-15 JP JP2013505169A patent/JP6085554B2/ja active Active
- 2011-04-15 PT PT117301200T patent/PT2558499T/pt unknown
- 2011-04-15 SG SG10201502967RA patent/SG10201502967RA/en unknown
- 2011-04-15 CA CA2794863A patent/CA2794863C/en active Active
- 2011-04-15 SM SM20170334T patent/SMT201700334T1/it unknown
- 2011-04-15 HR HRP20171045TT patent/HRP20171045T1/hr unknown
- 2011-04-15 HU HUE11730120A patent/HUE035098T2/en unknown
- 2011-04-15 ME MEP-2020-168A patent/ME03813B/me unknown
- 2011-04-15 LT LTEP11730120.0T patent/LT2558499T/lt unknown
- 2011-04-15 EP EP11730120.0A patent/EP2558499B1/en active Active
- 2011-04-15 KR KR1020127027585A patent/KR20130066584A/ko not_active Withdrawn
- 2011-04-15 NZ NZ602676A patent/NZ602676A/en unknown
- 2011-04-15 SG SG2012071999A patent/SG184318A1/en unknown
- 2011-04-15 ES ES18205524T patent/ES2912934T3/es active Active
- 2011-04-15 DK DK11730120.0T patent/DK2558499T3/en active
- 2011-04-15 PL PL17163411T patent/PL3202789T3/pl unknown
- 2011-04-15 MX MX2012012010A patent/MX340683B/es active IP Right Grant
- 2011-04-15 SM SM20200306T patent/SMT202000306T1/it unknown
2017
- 2017-01-30 JP JP2017014410A patent/JP6525440B2/ja active Active
- 2017-07-10 CY CY20171100728T patent/CY1119154T1/el unknown
- 2017-12-12 US US15/838,884 patent/US10335485B2/en active Active
2018
- 2018-05-15 JP JP2018093927A patent/JP2018123165A/ja not_active Withdrawn
2019
- 2019-06-14 US US16/441,974 patent/US11083791B2/en active Active
- 2019-10-09 JP JP2019185798A patent/JP2020019811A/ja active Pending
2020
- 2020-06-02 CY CY20201100516T patent/CY1122978T1/el unknown
- 2020-08-03 HR HRP20201219TT patent/HRP20201219T1/hr unknown
2021
- 2021-07-02 US US17/366,903 patent/US11571477B2/en active Active
2022
- 2022-07-22 JP JP2022117076A patent/JP7696317B2/ja active Active
2023
- 2023-02-06 US US18/165,146 patent/US20240100155A1/en active Pending

Also Published As

Publication number	Publication date
EP3202789B1 (en)	2020-05-06
WO2011130603A3 (en)	2012-03-08
PT3202789T (pt)	2020-06-16
SMT201700334T1 (it)	2017-09-07
BR112012026403A2 (pl)	2017-09-05
ES3039529T3 (en)	2025-10-22
JP2020019811A (ja)	2020-02-06
PL3466977T3 (pl)	2022-05-09
US20180221480A1 (en)	2018-08-09
EP3466977A1 (en)	2019-04-10
EA201291065A1 (ru)	2013-03-29
ES2805873T3 (es)	2021-02-15
RS60897B1 (sr)	2020-11-30
EP3466977B1 (en)	2022-01-05
LT3202789T (lt)	2020-06-10
MX340683B (es)	2016-07-21
JP7696317B2 (ja)	2025-06-20
US20140161794A1 (en)	2014-06-12
ES2633105T3 (es)	2017-09-19
ES2912934T3 (es)	2022-05-30
HRP20201219T1 (hr)	2021-02-05
EP3202789A1 (en)	2017-08-09
US20210401981A1 (en)	2021-12-30
AU2011239512B2 (en)	2016-01-21
JP6085554B2 (ja)	2017-02-22
SMT202000306T1 (it)	2020-07-08
PL2558499T3 (pl)	2017-10-31
SG184318A1 (en)	2012-11-29
RS56082B1 (sr)	2017-10-31
KR20130066584A (ko)	2013-06-20
CN103038257A (zh)	2013-04-10
SG10201502967RA (en)	2015-05-28
US11083791B2 (en)	2021-08-10
MX2012012010A (es)	2013-02-26
WO2011130603A2 (en)	2011-10-20
US20240100155A1 (en)	2024-03-28
AU2011239512A1 (en)	2012-10-18
SG10202112020VA (en)	2021-12-30
BR112012026403A8 (pt)	2018-01-02
SI3202789T1 (sl)	2020-11-30
HUE035098T2 (en)	2018-05-02
ME02793B (me)	2018-01-20
US20190365892A1 (en)	2019-12-05
CA2794863C (en)	2020-07-07
CY1122978T1 (el)	2021-10-29
ME03813B (me)	2021-04-20
SI2558499T1 (sl)	2017-08-31
BR112012026403B1 (pt)	2022-10-04
CY1119154T1 (el)	2018-02-14
DK2558499T3 (en)	2017-07-24
JP2018123165A (ja)	2018-08-09
CA2794863A1 (en)	2011-10-20
JP6525440B2 (ja)	2019-06-05
JP2022141875A (ja)	2022-09-29
HRP20171045T1 (hr)	2017-10-06
US10335485B2 (en)	2019-07-02
PT2558499T (pt)	2017-07-14
US11571477B2 (en)	2023-02-07
DK3466977T3 (en)	2022-04-11
DK3202789T3 (da)	2020-05-18
NZ602676A (en)	2015-02-27
EP2558499A2 (en)	2013-02-20
EP4032912A1 (en)	2022-07-27
LT2558499T (lt)	2017-07-25
EP2558499B1 (en)	2017-04-12
JP2013530681A (ja)	2013-08-01
JP2017123846A (ja)	2017-07-20
EP4032912B1 (en)	2025-05-28
HUE050858T2 (hu)	2021-01-28

Publication	Publication Date	Title
IL259826A (en)	2018-07-31	Anti-alphabetatisiar antibody
ZA201209004B (en)	2013-08-28	Anti-fgfr2 antibodies
GB201000467D0 (en)	2010-02-24	Antibodies
PT2581113T (pt)	2018-07-04	Anticorpo anti-tim-3
PT2530091T (pt)	2018-05-17	Anticorpo anti-dll3
IL221371A0 (en)	2012-10-31	Anti-lrp6 antibodies
PL2616489T3 (pl)	2017-07-31	Przeciwciało anty-huTNFR1
GB201103955D0 (en)	2011-04-20	Antibodies
GB201112056D0 (en)	2011-08-31	Antibodies
LT2703486T (lt)	2018-05-25	Anti-b7-h3 antikūnas
SG10201502967RA (en)	2015-05-28	Anti-vla-4 antibodies
PL2603528T3 (pl)	2017-07-31	Przeciwciała Fab-glikozylowane
GB201020738D0 (en)	2011-01-19	Antibodies
ZA201302459B (en)	2014-01-29	Antibodies
GB201002238D0 (en)	2010-03-31	Antibodies
EP2714074A4 (en)	2015-04-22	ANTIBODIES AGAINST EMR1
GB201007957D0 (en)	2010-06-30	Antibody
GB201005062D0 (en)	2010-05-12	Antibodies
GB201020751D0 (en)	2011-01-19	Antibodies
GB201017780D0 (en)	2010-12-01	Antibody